Literature DB >> 2298011

Clearance of vancomycin during continuous arteriovenous hemodiafiltration.

R Bellomo1, D Ernest, G Parkin, N Boyce.   

Abstract

The clearance of vancomycin during therapy with continuous arteriovenous hemodiafiltration (CAVHD) has been measured in vivo. Vancomycin clearances (n = 16) were 0.636 +/- 0.269 L/h (10.5 +/- 4.46 ml/min). Effective drug clearances were proportional to ultrafiltrate volumes, reflecting convective clearance. Clearances of vancomycin on CAVHD were approximately twice the values seen with continuous arteriovenous hemofiltration. These data allow construction of a dosing schedule for vancomycin therapy in patients receiving renal support via CAVHD.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2298011     DOI： 10.1097/00003246-199002000-00011

Source DB:  PubMed          Journal:  Crit Care Med        ISSN： 0090-3493            Impact factor:   7.598


  5 in total

Review 1.  Critical care in uraemic children.

Authors:  J U Leititis; M Brandis
Journal:  Pediatr Nephrol       Date:  1992-01       Impact factor: 3.714

Review 2.  Advances in the critical care of poisoned paediatric patients.

Authors:  W Banner; O D Timmons; D D Vernon
Journal:  Drug Saf       Date:  1994-01       Impact factor: 5.606

Review 3.  A review of continuous renal replacement therapy.

Authors:  C G Flynn
Journal:  Ir J Med Sci       Date:  1994-07       Impact factor: 1.568

Review 4.  Hemofiltration compared to hemodialysis for acute kidney injury: systematic review and meta-analysis.

Authors:  Jan O Friedrich; Ron Wald; Sean M Bagshaw; Karen E A Burns; Neill K J Adhikari
Journal:  Crit Care       Date:  2012-08-06       Impact factor: 9.097

Review 5.  Clinical review: use of vancomycin in haemodialysis patients.

Authors:  Vincent Launay-Vacher; Hassane Izzedine; Lucile Mercadal; Gilbert Deray
Journal:  Crit Care       Date:  2002-06-10       Impact factor: 9.097
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.